Lista de obras - Darius Lakdawalla - Dominio Público Uruguay

A Cost-Benefit Analysis of Using Evidence of Effectiveness in Terms of Progression Free Survival in Making Reimbursement Decisions on New Cancer Therapies

article

A response to the points by Manton and Williamson

artículo científico publicado en 2003

Aging and the Growth of Long-Term Care ⬇️

artículo científico publicado en 1999

An Economic Evaluation of the War on Cancer ⬇️

artículo científico publicado en 2009

An analysis of whether higher health care spending in the United States versus Europe is 'worth it' in the case of cancer

artículo científico publicado en 2012

An economic evaluation of the war on cancer

artículo científico publicado en 2010

Annual expenditures for nursing home care: private and public payer price growth, 1977 to 2004.

scientific article published on March 2009

Are Biopharmaceutical Budget Caps Good Public Policy?

Are investments in disease prevention complements? The case of statins and health behaviors

artículo científico publicado en 2014

Are the Young Becoming More Disabled? ⬇️

Are the young becoming more disabled?

artículo científico publicado en 2004

Burden of illness of diabetic macular edema: literature review

artículo científico publicado en 2010

Burden, timing, and relationship of cardiovascular hospitalization to mortality among Medicare beneficiaries with newly diagnosed atrial fibrillation

artículo científico publicado en 2013

Can Oral Nutritional Supplements Improve Medicare Patient Outcomes in the Hospital?

artículo científico publicado en 2014

Careful use of science to advance the debate on the UK Cancer Drugs Fund

artículo científico publicado en 2014

Catastrophe Bonds, Reinsurance, and the Optimal Collateralization of Risk Transfer

Catastrophe Bonds, Reinsurance, and the Optimal Collateralization of Risk-Transfer ⬇️

artículo científico publicado en 2006

Chronic disease and severe disability among working-age populations

artículo científico publicado en 2008

Clinical evidence inputs to comparative effectiveness research could impact the development of novel treatments

Comparative effectiveness of antiarrhythmic drugs on cardiovascular hospitalization and mortality in atrial fibrillation

artículo científico

Defense Costs of Medical Malpractice Claims

Differences in health between Americans and Western Europeans: Effects on longevity and public finance

artículo científico publicado en 2011

Does Intellectual Property Restrict Output? An Analysis of Pharmaceutical Markets

artículo científico publicado en 2012

Does Medicare Benefit the Poor? New Answers to an Old Question ⬇️

artículo científico publicado en 2002

Does Medicare Coverage Improve Cancer Detection and Mortality Outcomes? ⬇️

artículo científico publicado en 2019

Does Medicare benefit the poor?

Economic burden of community-based disease-associated malnutrition in the United States.

artículo científico publicado en 2014

Economic burden of disease-associated malnutrition in China

artículo científico publicado en 2014

Economic instruments for obesity prevention: results of a scoping review and modified Delphi survey

artículo científico publicado en 2011

Effect of hospital use of oral nutritional supplementation on length of stay, hospital cost, and 30-day readmissions among Medicare patients with COPD.

artículo científico publicado en 2015

Effects of Expanding Health Screening on Treatment - What Should We Expect? What Can We Learn? ⬇️

artículo científico publicado en 2018

Erratum: Valuing health technologies at NICE: recommendations for improved incorporation of treatment value in HTA

article

Estimating the Value of New Technologies That Provide More Accurate Drug Adherence Information to Providers for Their Patients with Schizophrenia

artículo científico publicado en 2016

Estimating the future burden of cardiovascular disease and the value of lipid and blood pressure control therapies in China

artículo científico publicado en 2016

Evaluating Expected Costs and Benefits of Granting Access to New Treatments on the Basis of Progression-Free Survival in Non-Small-Cell Lung Cancer

artículo científico publicado en 2015

Evaluation of Medical Technologies with Uncertain Benefits ⬇️

Food Prices and the Dynamics of Body Weight ⬇️

artículo científico publicado en 2009

Food Prices, Income, and Body Weight

Forecasting the nursing home population.

artículo científico publicado en 2003

Freedom to Innovate: The Perils of Centralized Medical Research

Geographic Variation in Health Care: The Role of Private Markets

article

HIV Breakthroughs and Risk Sexual Behavior ⬇️

artículo científico publicado en 2004

HIV Breakthroughs and Risky Sexual Behavior*

article

HOW DOES HEALTH INSURANCE AFFECT WORKERS’ COMPENSATION FILING?

article

HOW DOES TERRORISM RISK VARY ACROSS SPACE AND TIME? AN ANALYSIS BASED ON THE ISRAELI EXPERIENCE

scholarly article by Claude Berrebi & Darius Lakdawalla published April 2007 in Defence and Peace Economics

Healing the Poor: The Influence of Patient Socioeconomic Status on Physician Supply Responses ⬇️

artículo científico publicado en 2016

Health Insurance as a Two-Part Pricing Contract

artículo científico publicado en 2013

Health Insurance as a Two-Part Pricing Contract ⬇️

artículo científico publicado en 2006

How cancer patients value hope and the implications for cost-effectiveness assessments of high-cost cancer therapies.

artículo científico publicado en 2012

Impact of oral nutrition supplements on hospital outcomes in pediatric patients

artículo científico publicado en 2014

Incentives to Innovate

Innovation and The Welfare Effects of Public Drug Insurance

artículo científico publicado en 2009

Insurance and Innovation in Health Care Markets ⬇️

Insurance, Self-Protection, and the Economics of Terrorism ⬇️

artículo científico publicado en 2002

Insurance, self-protection, and the economics of terrorism

Insurer Bargaining and Negotiated Drug Prices in Medicare Part D ⬇️

artículo científico publicado en 2009

Insurers' Negotiating Leverage and the External Effects of Medicare Part D

artículo científico publicado en 2015

Insurers' Negotiating Leverage and the External Effects of Medicare Part D ⬇️

artículo científico publicado en 2010

Intellectual Property and Marketing ⬇️

artículo científico publicado en 2006

Intellectual Property, Information Technology, Biomedical Research, and Marketing of Patented Products

scholarly article published 2011

International Differences in Longevity and Health and their Economic Consequences ⬇️

artículo científico publicado en 2009

Malpractice risk according to physician specialty

artículo científico publicado en 2011

Market Exclusivity For Drugs: The Authors Reply

Medical professional liability risk among US cardiologists

artículo científico publicado en 2014

Mortality Risk, Insurance, and the Value of Life ⬇️

artículo científico publicado en 2018

Nonprofit Production and Competition ⬇️

artículo científico publicado en 1998

On average, physicians spend nearly 11 percent of their 40-year careers with an open, unresolved malpractice claim.

artículo científico

Optimal Liability for Terrorism ⬇️

artículo científico publicado en 2006

Outcomes of medical malpractice litigation against US physicians

artículo científico publicado en 2012

Patents, innovation, and the welfare effects of Medicare Part D.

artículo científico publicado en 2010

Patient Outcomes and Cost Effects of Medicaid Formulary Restrictions on Antidepressants

artículo científico publicado en 2014

Patients value metastatic cancer therapy more highly than is typically shown through traditional estimates

artículo científico publicado en 2012

Patients’ Willingness To Pay: The Authors Reply

Patterns of Adherence to Oral Atypical Antipsychotics Among Patients Diagnosed with Schizophrenia

artículo científico publicado en 2016

Pharmaceutical advertising and Medicare Part D

artículo científico publicado en 2013

Predicting quantity and quality of life with the Future Elderly Model

artículo científico publicado en 2020

Prescription Drug Advertising and Drug Utilization: The Role of Medicare Part D ⬇️

artículo científico publicado en 2015

Public-Private Partnership as a Path to Affordable Healthcare in Emerging Markets

article

Quality-adjusted cost of care: a meaningful way to measure growth in innovation cost versus the value of health gains

artículo científico publicado en 2015

Quantifying Gains in the War on Cancer Due to Improved Treatment and Earlier Detection

scientific article published on 01 June 2016

Reforming medicare's dialysis payment policies: implications for patients with secondary hyperparathyroidism

artículo científico publicado en 2014

Social insurance and the design of innovation incentives

article

The Declining Quality of Teachers ⬇️

artículo científico publicado en 2001

The Economics of Teacher Quality

The Growth of Obesity and Technological Change: A Theoretical and Empirical Examination ⬇️

artículo científico publicado en 2002

The Insurance Value of Medical Innovation ⬇️

artículo científico publicado en 2015

The Relationship between Commercial Health Care Prices and Medicare Spending and Utilization

artículo científico publicado en 2014

The Rise in Old Age Longevity and the Market for Long-Term Care ⬇️

artículo científico publicado en 1998

The Rise in Old-Age Longevity and the Market for Long-Term Care

artículo científico publicado en 2002

The Welfare Effects of Medical Malpractice Liability

artículo científico publicado en 2012

The Welfare Effects of Medical Malpractice Liability ⬇️

artículo científico publicado en 2009

The Welfare Effects of Public Drug Insurance ⬇️

artículo científico publicado en 2007

The benefits from giving makers of conventional 'small molecule' drugs longer exclusivity over clinical trial data

artículo científico publicado en 2011

The effect of regulation on pharmaceutical revenues: experience in nineteen countries

scientific article published on 16 December 2008

The growth of obesity and technological change

scientific article published on 26 August 2009

The impact of insulin type on severe hypoglycaemia events requiring inpatient and emergency department care in patients with type 2 diabetes

artículo científico publicado en 2013

The insurance value of medical innovation

article

The large social value resulting from use of statins warrants steps to improve adherence and broaden treatment

artículo científico publicado en 2012

The nonprofit sector and industry performance

article

The role of imperfect surrogate endpoint information in drug approval and reimbursement decisions

artículo científico publicado en 2016

The value of medical and pharmaceutical interventions for reducing obesity

artículo científico publicado en 2012

The value of specialty oncology drugs

artículo científico publicado en 2009

The value of surrogate endpoints for predicting real-world survival across five cancer types

artículo científico publicado en 2016

Time-Inconsistency and Welfare ⬇️

artículo científico publicado en 2004

U.S. pharmaceutical policy in a global marketplace

artículo científico publicado en 2008

Understanding Health Disparities Across Education Groups ⬇️

artículo científico publicado en 2001

Understanding the Economic Consequences of Shifting Trends in Population Health ⬇️

artículo científico publicado en 2009

Unintended Consequences of Products Liability: Evidence from the Pharmaceutical Market ⬇️

artículo científico publicado en 2014

Valuing health technologies at NICE: recommendations for improved incorporation of treatment value in HTA.

artículo científico publicado en 2010

Want More Value from Prescription Drugs? We Need to Let Prices Rise and Fall

Welfare-Enhancing Technological Change and the Growth of Obesity

artículo científico publicado en 2005

Lista de obras de Darius Lakdawalla

A Cost-Benefit Analysis of Using Evidence of Effectiveness in Terms of Progression Free Survival in Making Reimbursement Decisions on New Cancer Therapies

A response to the points by Manton and Williamson

Aging and the Growth of Long-Term Care ⬇️

An Economic Evaluation of the War on Cancer ⬇️

An analysis of whether higher health care spending in the United States versus Europe is 'worth it' in the case of cancer

An economic evaluation of the war on cancer

Annual expenditures for nursing home care: private and public payer price growth, 1977 to 2004.

Are Biopharmaceutical Budget Caps Good Public Policy?

Are investments in disease prevention complements? The case of statins and health behaviors

Are the Young Becoming More Disabled? ⬇️

Are the young becoming more disabled?

Burden of illness of diabetic macular edema: literature review

Burden, timing, and relationship of cardiovascular hospitalization to mortality among Medicare beneficiaries with newly diagnosed atrial fibrillation

Can Oral Nutritional Supplements Improve Medicare Patient Outcomes in the Hospital?

Careful use of science to advance the debate on the UK Cancer Drugs Fund

Catastrophe Bonds, Reinsurance, and the Optimal Collateralization of Risk Transfer

Catastrophe Bonds, Reinsurance, and the Optimal Collateralization of Risk-Transfer ⬇️

Chronic disease and severe disability among working-age populations

Clinical evidence inputs to comparative effectiveness research could impact the development of novel treatments

Comparative effectiveness of antiarrhythmic drugs on cardiovascular hospitalization and mortality in atrial fibrillation

Defense Costs of Medical Malpractice Claims

Differences in health between Americans and Western Europeans: Effects on longevity and public finance

Does Intellectual Property Restrict Output? An Analysis of Pharmaceutical Markets

Does Medicare Benefit the Poor? New Answers to an Old Question ⬇️

Does Medicare Coverage Improve Cancer Detection and Mortality Outcomes? ⬇️

Does Medicare benefit the poor?

Economic burden of community-based disease-associated malnutrition in the United States.

Economic burden of disease-associated malnutrition in China

Economic instruments for obesity prevention: results of a scoping review and modified Delphi survey

Effect of hospital use of oral nutritional supplementation on length of stay, hospital cost, and 30-day readmissions among Medicare patients with COPD.

Effects of Expanding Health Screening on Treatment - What Should We Expect? What Can We Learn? ⬇️

Erratum: Valuing health technologies at NICE: recommendations for improved incorporation of treatment value in HTA

Estimating the Value of New Technologies That Provide More Accurate Drug Adherence Information to Providers for Their Patients with Schizophrenia

Estimating the future burden of cardiovascular disease and the value of lipid and blood pressure control therapies in China

Evaluating Expected Costs and Benefits of Granting Access to New Treatments on the Basis of Progression-Free Survival in Non-Small-Cell Lung Cancer

Evaluation of Medical Technologies with Uncertain Benefits ⬇️

Food Prices and the Dynamics of Body Weight ⬇️

Food Prices, Income, and Body Weight

Forecasting the nursing home population.

Freedom to Innovate: The Perils of Centralized Medical Research

Geographic Variation in Health Care: The Role of Private Markets

HIV Breakthroughs and Risk Sexual Behavior ⬇️

HIV Breakthroughs and Risky Sexual Behavior*

HOW DOES HEALTH INSURANCE AFFECT WORKERS’ COMPENSATION FILING?

HOW DOES TERRORISM RISK VARY ACROSS SPACE AND TIME? AN ANALYSIS BASED ON THE ISRAELI EXPERIENCE

Healing the Poor: The Influence of Patient Socioeconomic Status on Physician Supply Responses ⬇️

Health Insurance as a Two-Part Pricing Contract

Health Insurance as a Two-Part Pricing Contract ⬇️

How cancer patients value hope and the implications for cost-effectiveness assessments of high-cost cancer therapies.

Impact of oral nutrition supplements on hospital outcomes in pediatric patients

Incentives to Innovate

Innovation and The Welfare Effects of Public Drug Insurance

Insurance and Innovation in Health Care Markets ⬇️

Insurance, Self-Protection, and the Economics of Terrorism ⬇️

Insurance, self-protection, and the economics of terrorism

Insurer Bargaining and Negotiated Drug Prices in Medicare Part D ⬇️

Insurers' Negotiating Leverage and the External Effects of Medicare Part D

Insurers' Negotiating Leverage and the External Effects of Medicare Part D ⬇️

Intellectual Property and Marketing ⬇️

Intellectual Property, Information Technology, Biomedical Research, and Marketing of Patented Products

International Differences in Longevity and Health and their Economic Consequences ⬇️

Malpractice risk according to physician specialty

Market Exclusivity For Drugs: The Authors Reply

Medical professional liability risk among US cardiologists

Mortality Risk, Insurance, and the Value of Life ⬇️

Nonprofit Production and Competition ⬇️

On average, physicians spend nearly 11 percent of their 40-year careers with an open, unresolved malpractice claim.

Optimal Liability for Terrorism ⬇️

Outcomes of medical malpractice litigation against US physicians

Patents, innovation, and the welfare effects of Medicare Part D.

Patient Outcomes and Cost Effects of Medicaid Formulary Restrictions on Antidepressants

Patients value metastatic cancer therapy more highly than is typically shown through traditional estimates

Patients’ Willingness To Pay: The Authors Reply

Patterns of Adherence to Oral Atypical Antipsychotics Among Patients Diagnosed with Schizophrenia

Pharmaceutical advertising and Medicare Part D

Predicting quantity and quality of life with the Future Elderly Model

Prescription Drug Advertising and Drug Utilization: The Role of Medicare Part D ⬇️

Public-Private Partnership as a Path to Affordable Healthcare in Emerging Markets

Quality-adjusted cost of care: a meaningful way to measure growth in innovation cost versus the value of health gains